Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy
Our study has shown a trend toward the need for checking E2 levels to assess for incomplete OFS and that changing GnRH agonist agent can improve rates of complete OFS for some patients. Additionally, our study has shown that chemotherapy naïve patients experience more incomplete OFS; however, further data is needed to validate these results.
Authors
- Alexandra Halbach
- Sailaja Kamaraju (ORCID: https://orcid.org/0000-0003-3031-9269)
- Maressa Sweeney
- Ruchi P. Patel (ORCID: https://orcid.org/0000-0001-8366-1928)
- Yee Chung Cheng (ORCID: https://orcid.org/0009-0009-1309-0758)
- Colin Mooney (ORCID: https://orcid.org/0000-0003-4923-8119)
- John Burfeind
- Emma Carroll (ORCID: https://orcid.org/0000-0003-4570-387X)
- Kim Vanessa Steinke (ORCID: https://orcid.org/0000-0002-0570-1776)
- Janet Retseck (ORCID: https://orcid.org/0009-0009-4911-4803)
- Lubna N. Chaudhary (ORCID: https://orcid.org/0000-0003-0616-6135)
- Jutta Deininger
- Elizabeth Weil (ORCID: https://orcid.org/0000-0001-7357-7669)
- Deepika Sriram
- Sara Bugamelli
- Erinn Stockhausen
Institutions
- Froedtert Hospital (US)
- Medical College of Wisconsin (US)
- National Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1186/s13058-025-01979-x
- Citations
- 2
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.87